Prothena Corp
PRTA
About: Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.
Employees: 163
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
136% more first-time investments, than exits
New positions opened: 52 | Existing positions closed: 22
32% more repeat investments, than reductions
Existing positions increased: 54 | Existing positions reduced: 41
18% more funds holding
Funds holding: 159 [Q1] → 187 (+28) [Q2]
6% more call options, than puts
Call options by funds: $6.7M | Put options by funds: $6.34M
0% more funds holding in top 10
Funds holding in top 10: 3 [Q1] → 3 (+0) [Q2]
19.46% less ownership
Funds ownership: 97.07% [Q1] → 77.61% (-19.46%) [Q2]
61% less capital invested
Capital invested by funds: $647M [Q1] → $254M (-$393M) [Q2]
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
5 analyst ratings
|
JMP Securities
Jason Butler
|
$11
|
Market Outperform
Maintained
|
2 Sep 2025 |
|
Piper Sandler
Yasmeen Rahimi
|
$15
|
Overweight
Maintained
|
28 Aug 2025 |
|
Chardan Capital
Rudy Li
|
$18
|
Buy
Maintained
|
28 Aug 2025 |
|
RBC Capital
Brian Abrahams
|
$10
|
Sector Perform
Maintained
|
5 Aug 2025 |
|
HC Wainwright & Co.
Andrew S. Fein
|
$14
|
Buy
Reiterated
|
5 Aug 2025 |
Financial journalist opinion
Based on 4 articles about PRTA published over the past 30 days
